Roche gets to work on US investment plan with reveal of $700M obesity drug plant in North Carolina
Roche has earmarked more than $700 million to construct a sprawling new plant for its Genentech unit in Holly Springs, North Carolina. The new plant, which will be used for fill and finish of next-generation obesity drugs, forms part of a broader $50 billion, five-year U.S. investment plan Roche unveiled last month.
Roche has earmarked more than $700 million to construct a sprawling new plant for its Genentech unit in Holly Springs, North Carolina. The new plant, which will be used for fill and finish of next-generation obesity drugs, forms part of a broader $50 billion, five-year U.S. investment plan Roche unveiled last month.
